Deucravacitinib
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus
Trial Timeline
Jan 12, 2023 → Nov 13, 2028
NCT ID
NCT05617677About Deucravacitinib
Deucravacitinib is a phase 3 stage product being developed by Bristol Myers Squibb for Systemic Lupus Erythematosus. The current trial status is active. This product is registered under clinical trial identifier NCT05617677. Target conditions include Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06979453 | Phase 3 | Recruiting |
| NCT07256015 | Pre-clinical | Recruiting |
| NCT06869551 | Phase 3 | Recruiting |
| NCT06725264 | Phase 2 | Withdrawn |
| NCT06701513 | Pre-clinical | Recruiting |
| NCT06512337 | Pre-clinical | Recruiting |
| NCT06566768 | Phase 1 | Completed |
| NCT06258668 | Pre-clinical | Recruiting |
| NCT06476834 | Approved | Completed |
| NCT05821374 | Phase 1 | Withdrawn |
| NCT06091956 | Phase 2 | Completed |
| NCT05858645 | Approved | Recruiting |
| NCT05946941 | Phase 3 | Active |
| NCT06104644 | Pre-clinical | Active |
| NCT05701995 | Approved | Completed |
| NCT05617677 | Phase 3 | Active |
| NCT05620407 | Phase 3 | Active |
| NCT05556265 | Phase 2 | Terminated |
| NCT05478499 | Approved | Completed |
| NCT04908202 | Phase 3 | Active |
Competing Products
20 competing products in Systemic Lupus Erythematosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 33 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Phase 2 | 52 |
| E6742 | Eisai | Phase 1/2 | 41 |
| KHK4827 | Kyowa Kirin | Phase 1 | 33 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 33 |